西安“学术金秋”聚焦外泌体前沿 细胞科技领域取得国际备案新进展

Core Insights - The forum focused on the latest developments in exosome technology and the progress of local cell technology companies in achieving international compliance for related raw materials [1][3][5] Group 1: Event Overview - The forum, themed "Exploring Cell Messengers Leading the Future of Regeneration," was held in Xi'an and co-hosted by the Xi'an Science and Technology Association and the Xi'an High-tech Zone Management Committee [1][3] - It attracted participation from academic experts, government representatives, clinical researchers, and industry professionals, highlighting the application potential of exosomes in regenerative medicine and disease diagnosis [3][5] Group 2: Key Presentations - Renowned scientist Academician Pei Duanqing provided insights into the development trends, scientific value, and future prospects of exosome technology, emphasizing its potential in regenerative medicine, disease diagnosis, and new drug development [5] - He noted that the standardization and industrialization of exosomes are essential directions for the future [5] Group 3: Industry Developments - The forum announced that local company Medcell Biotechnology's exosome raw materials have received FDA DMF (Drug Master File) registration and have been included in the International Cosmetic Ingredient (INCI) list [5] - This FDA DMF registration indicates that the raw materials meet pharmaceutical-grade regulatory standards, facilitating their application in innovative drug development, while inclusion in the INCI list opens opportunities in the cosmetics sector [5] Group 4: Collaborative Efforts - A ceremony for "Building an Innovative Ecosystem for the Exosome Industry" was held, showcasing the collective commitment of academicians, university representatives, and business leaders to advance exosome technology from laboratory research to industrial application [7] - Collaborating institutions include Shaanxi Normal University and Northwestern Polytechnical University, contributing to the promotion of industry-academia-research cooperation in the biopharmaceutical frontier [7]